TSX open
Loading markets…

Advertisement

PARTNER SPOTLIGHT

CIBC Investor's Edge

Invest your way with confidence.

  • ✓Powerful tools & research — at no extra cost
  • ✓Stocks, ETFs, options & more
  • ✓Competitive fees + USD accounts
Stocks/TSX/HLS

HLS Therapeutics Inc (HLS : TSX)

Common Stock

$4.21

CAD

+0.34 (8.79%)

Last updated: 2026-10-05

Follow HLS

HLS

HLS Therapeutics Inc

Source:WealthAwesomeWealthAwesome
↑ $0.52 (14.09%)
30 day period
$3.60$3.91$4.21Aug 24Sep 15Oct 5

Performance

1 Day

+8.79%

1 Week

+5.25%

1 Month

+13.78%

YTD

-13.20%

Key Statistics

Market Cap

$130.24M

52W High

$5.72

52W Low

$3.56

P/E Ratio

-

50 Day MA

$3.93

200 Day MA

$4.37

Beta

0.76

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

↑Above 50 SMA

Price vs 200-Day SMA

↓Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
10/5/2026$3.90$4.25$3.90$4.21$4.21437,761
10/2/2026$4.00$4.11$3.86$3.87$3.8751,573
10/1/2026$4.17$4.20$3.75$3.89$3.89388,870
9/30/2026$4.00$4.20$4.00$4.20$4.20104,800
9/29/2026$4.02$4.02$3.95$3.99$3.9919,100
9/28/2026$3.99$4.01$3.99$4.00$4.0028,150
9/25/2026$4.00$4.04$3.94$4.02$4.02370,338
9/24/2026$3.92$4.00$3.91$3.94$3.9449,845
9/23/2026$4.00$4.00$3.86$3.95$3.9512,553
9/22/2026$3.97$4.01$3.96$3.96$3.968,688

Analyst Price Targets

Based on analyst covering HLS · as of Oct 6, 2026

📈

Wall Street analysts forecast HLS stock price to rise 78.6% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$7.52

+78.6% Upside

Previously C$7.51 on Oct 5, 2026

Current Price

C$4.21

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on HLS's historical volatility

HistoricalForecast68%95%
C$2.15C$3.29C$4.43C$5.57C$6.70C$7.84TodayMay 28Jul 31Oct 5Nov 17Dec 31Feb 12

30-Day Vol

51.7%

Annualized

90-Day Vol

38.7%

Annualized

Trend (90d)

-6.9%

Annualized drift

90d Mean

C$4.11

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$4.18C$3.49 – C$4.99
60 trading daysC$4.14C$3.22 – C$5.33
90 trading daysC$4.11C$3.02 – C$5.59

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About HLS Therapeutics Inc

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Financials

Revenue (TTM)
$56.24M
EBITDA
$17.01M
Profit Margin
-15.24%
ROE (TTM)
-14.07%
EPS (Diluted)
-0.37
Book Value
2.52

Classification

Sector
Health Care
Industry
Pharmaceuticals
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About HLS

Market movers

Recent TSX movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
CJR-BCorus Entertainment Inc$0.04+16.67%
AVNTAvant Brands Inc$0.59+15.69%
ACBAurora Cannabis Inc$6.37+14.16%
ABXXAbaxx Technologies Inc.$19.76+13.82%
ATHAthabasca Oil Corp$12.01+13.52%
CFFConifex Timber Inc$0.11+10.00%
MCBMccoy Global Inc$2.47+9.78%
RUARua Gold Inc.$1.34+8.94%

HLS.TO news timeline

15 articles covering HLS.TO, most recent first

Latest

Why HLS Therapeutics Inc stock surged yesterday

•Stocks

Advertisement